Hirsch Andrew 4

What Happened
Andrew Hirsch, President & CEO and a director of C4 Therapeutics (CCCC), was granted 700,000 restricted stock units (RSUs) on Feb 13, 2026. In addition, previously awarded RSUs vested and converted into 102,125 shares on Feb 14–15, 2026 (reported as "M" — exercise/conversion of derivative, $0 cost). To satisfy tax withholding obligations, 48,211 of those shares were withheld (reported as "F") at $1.89 per share for cash value of $74,001 (39,154 shares) on Feb 14 and $17,118 (9,057 shares) on Feb 15. Net share increase from these vest/settlements: 53,914 shares.

Key Details

• Grant: 700,000 RSUs granted 2026-02-13 (reported as "A"), acquisition price $0.
• Vesting conversions: 81,725 shares acquired 2026-02-14 and 20,400 shares acquired 2026-02-15 (both "M", $0).
• Tax withholding: 39,154 shares withheld 2/14 for $74,001 and 9,057 shares withheld 2/15 for $17,118 (both "F"); total withheld value $91,119. These withholdings are not open-market sales by Hirsch.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 explains the 700K RSU vesting schedule (350,000 vest in three equal annual installments beginning Feb 13, 2027; remaining 350,000 vest in full on Feb 13, 2029, subject to performance acceleration). F2 notes the converted shares came from previously disclosed RSU grants (reported in prior Forms 4). F3 clarifies withheld shares satisfy tax obligations and are not a sale.
• Filing: Form filed 2026-02-18 reporting transactions dated Feb 13–15, 2026. Form 4s are typically due within two business days of a transaction; the filing date is shown as Feb 18.

Context

• "M" transactions here reflect conversion/vesting of RSUs or other derivatives into common stock; the conversions recorded $0 acquisition price because the shares resulted from vested RSUs.
• "F" entries represent shares withheld by the company to cover taxes, not an open-market sale — common practice on RSU settlements.
• This filing reports award and routine vesting/withholding activity; it is factual disclosure and does not by itself indicate insider sentiment about the stock.